Iron­wood re­cruits CMO on the eve of split-up; Roche vet Margrit Schwarz joins Genevant

→ Iron­wood Phar­ma­ceu­ti­cals is fill­ing up its C-suite to pre­pare for the im­pend­ing split up in­to two en­ti­ties. Just a week af­ter tap­ping As­traZeneca’s Mark Mal­lon for the CEO job, the com­pa­ny has ap­point­ed Michael Shet­z­line as CMO of the com­mer­cial-fo­cused unit, tasked with stew­ard­ing ex­ist­ing gas­troin­testi­nal as­sets, in­clud­ing its fran­chise drug Linzess, as well as find­ing new prod­uct op­por­tu­ni­ties in the space. He will re­port to Thomas Mc­Court, the cur­rent chief com­mer­cial of­fi­cer who’s get­ting pro­mot­ed to pres­i­dent as found­ing CEO Pe­ter Hecht leaves to run the R&D spin­out.  

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER